看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
% U# p e3 H6 @# J1 f+ s) D9 H
) _9 ~- e( n- x4 V- W( \* [4 d
5 U" k8 |% U- @( M2 @' V" k6 p% A; FCurrently available feasibility data for possible combination strategies. % E0 a. ]5 E. [: T$ e6 P
————————————————————————————————
) ?$ k: U2 i4 Q% ?7 o2 ^" n+ W5 aCombination Feasibility according to preliminary data / y$ T* t8 o* B9 p
——————————————————————————————————
: g. G4 {1 L+ i- N0 ~Bevacizumab + sorafenib Yes, reduced dose
' g& [: }6 ?" |Bevacizumab + sunitinib† No p9 S' d3 t6 k3 i, ?7 X' d; x
Bevacizumab + temsirolimus Yes
1 m, i, q$ ~) m" ^ m# UBevacizumab + everolimus Yes - i D* N/ h7 a# K2 f; ]' B
Sorafenib + sunitinib ? % G% C+ V0 c" ]8 m4 j3 m
Sorafenib + temsirolimus Yes, reduced dose ( S/ s! A9 Q+ o2 Q0 H$ z) ^5 \
Sorafenib + everolimus Yes, reduced dose
. k* W* t2 W& B6 J3 u2 d* MSunitinib + temsirolimus† No ' G( K( C6 K2 K# B& S
Sunitinib + everolimus ? % S2 _$ J3 s% y; j& P
Temsirolimus + everolimus ? 3 x, S) i8 T2 ~# z; j7 s7 S6 D' R
————————————————————
% n# x( o9 z8 K$ r2 z) {( P†Led to US FDA warning.. P2 t( R( | I8 b; O
?: As yet unattempted combination.
. h( D- f+ E5 O7 C |